Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS-101 in Treatment-Naïve Neovascular Age-Related Macular Degeneration
NCT07798375Phase 2Not yet recruiting
- Sponsor
- Everest Medicines
- Start
- Sep 2026
- Primary completion
- May 2028
01
Overview
A Phase 2 trial of ASKG712 in neovascular age-related macular degeneration (NVAMD), sponsored by Everest Medicines. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ASKG712
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07798375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07798375.